How were Prana Biotechnology's earnings last quarter?

Prana Biotechnology Limited (ASX:PBT) released its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

ASX:PBT

Prana Biotechnology (PBT) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free PBT Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Prana Biotechnology alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Prana Biotechnology

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

PBT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive PBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:PBT
CUSIP: N/A
CIK: N/A
Web: pranabio.com
Phone: +61-3-93494906
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 567,500,992
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Geoffrey Paul Kempler (Age 64)
Co-Founder, Exec. Chairman, CEO & MD
Ms. Kathryn Andrews (Age 52)
Chief Financial Officer
Dr. David A. Stamler (Age 58)
Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board
Prof. Rudolph Emile Tanzi
Chief Scientific Advisor and Member of R&D Advisory Board
Dr. Steven D. Targum M.D.
Chief Medical Advisor

Key Competitors

View All Competitors

PBT Stock Analysis - Frequently Asked Questions

How were Prana Biotechnology's earnings last quarter?: Prana Biotechnology Limited (ASX:PBT) released its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

This page (ASX:PBT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial